NCT05962606 2026-03-18
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
Aptarion Biotech AG
Phase 2 Completed
Aptarion Biotech AG
National Cancer Institute (NCI)
BioAegis Therapeutics Inc.
Nantes University Hospital
M.D. Anderson Cancer Center
MedImmune LLC